
PCI Biotech



ABG Sundal Collier Norwegian Oncology Seminar September 14, 2021 Per Walday, CEO



Important notice and disclaimer

This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on PCI Biotech's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "programmes", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of PCI Biotech's strategy and its ability to further grow, risks associated with the development and/or approval of PCI Biotech's products candidates, ongoing clinical trials and expected trial results, the ability to commercialise fimaporfin (Amphinex[®]), technology changes and new products in PCI Biotech's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The reservation is also made that inaccuracies or mistakes may occur in this information given about current status of the Company or its business. Any reliance on the information is at the risk of the reader, and PCI Biotech disclaims any and all liability in this respect.



PCI BIOTECH – ENABLING INTRACELLULAR DELIVERY

- ► A biotech company with an oncology focused pipeline
 - A listed (PCIB:NO) cancer-focused biotech company
 - Cash position at Q2 of NOK 147 mill, partly placed in Euro
 - Photochemical internalisation ("PCI") technology for intracellular delivery
 - One platform technology with three well differentiated assets

Programme	Indications/Therapeutics	Preclinical	Phase I	Phase II	Pivotal
G fima <i>CHEM</i>	Bile duct cancer / gemcitabine				
fima VACC	Therapeutic cancer vaccines				
fimaNAc	Nucleic acid therapeutics				
Photochemical internalisation (PCI) is a platform technology with three programmes					

targeting an attractive and growing oncology market



fima *CHEM* – first line treatment for the orphan indication bile duct cancer



Positive early clinical results

Encouraging tumour response and survival data

Pathway to market settled by regulatory interactions

 Single pivotal study with potential accelerated approval based on interim analysis

RELEASE – a global pivotal registration intent study

 Recruitment ongoing at approx. 50 hospitals across three continents



fima*CHEM*

- Excellent fit with medical need and existing treatments
- Efficacy: mOS¹ of 22.8 months at selected dose (cohort IV) in Phase I dose-escalation (vs. 11-12 months² with standard of care for inoperable bile duct cancer treatments)
- Easy to use: Illumination through standard endoscopic methods compatible with endoscopic stenting for palliative biliary drainage
- Positioning: Enhances recommended first-line chemotherapy and boosts effect locally, where it is most needed (no direct competition)
- **Protection:** Orphan Drug designations in EU, US and South Korea offers potential market exclusivity
- Competition: Precision/gene/small molecules in clinical development are mainly second line or towards targets mainly present in intrahepatic bile duct cancer
- Premium price potential: Mean price for OD in the US is \$K150 (median \$K109)³



BILE DUCT CANCER – PHASE I DOSE-ESCALATION STUDY


- Positive early signs of efficacy median Overall Survival of 22.8 months at selected dose
- Encouraging tumour response and survival in Cohort IV, with a single fimaCHEM treatment
- Cohort IV dose has been selected for the pivotal RELEASE study
- Phase I case reports published in peer-reviewed medical journal (open access)*
- ▶ Results paved the way for a pivotal study with interim analysis for potential accelerated approval

Parameters	Cohort IV (N=6)	Phase I – all dose-escalation cohorts (N=16)
Objective Response Rate (ORR)	3/5 patients (2 PR; 1 CR)	4/12 patients (2 PR; 2 CR)
Median Overall Survival (mOS)	22.8 months	16.1 months



BILE DUCT CANCER – RELEASE STUDY

Pivotal study with potential accelerated/conditional approval on interim analysis





BILE DUCT CANCER – RELEASE STUDY

- Pivotal study status
- Open sites in South Korea, Taiwan, USA and 11 European countries
- Enrolling patients across three continents, with 47 sites open for patient enrolment at Q2'21
- 9 sites open in Asia and 6 sites in the US
- Screening in the RELEASE study has been affected by the COVID-19 pandemic
- Several initiatives implemented with the aim to recoup the COVID-19 caused delay, the most important being:
 - Eligibility criteria modifications
 - Study expansion, including Asia






BILE DUCT CANCER – RELEASE STUDY DESIGN

- Randomised study with interim analysis for potential accelerated/conditional approval
 - Orphan designation granted in the US, EU and South Korea
 - ► Fastest way to market determined through regulatory interactions with authorities
 - Formal interim analysis of ORR when 120 patients are enrolled
 - Interim read for potential accelerated approval expected 2H 2023
- ► Interim analysis primary endpoint: ORR^a
- Final analysis primary endpoint: PFS^b, with OS^c as key secondary

- Several initiatives to enhance recruitment implemented and study expanded to Asia autumn 2020
 - Increased screening and enrolment after implementation, but still fluctuating
 - Full effect of the initiatives not expected until the COVID-19 situation improves further



fima VACC – aiming to enhance the effect of immunotherapeutics



Compelling preclinical results

Particularly strong CD8 T-cell immune responses

Successfully translated into humans

 Phase I study in healthy volunteers with peptideand protein-based vaccines


Versatile vaccination platform

 Can potentially be used with several modalities, including nucleic acid based technologies



SUCCESSFUL CLINICAL PROOF-OF-CONCEPT IN HEALTHY VOLUNTEERS

Phase I study shows enhanced immune responses compared to a state-of-the-art adjuvant



fimaVACC provides:

- ✓ Increased number of responders
- Enhanced T-cell responses
- Improved T-cell functionality

- Results show that the addition of fimaVACC induces:
 - Substantial increase in number of T-cell responders to HPV E7 peptides
 - Clearly enhanced overall T-cell responses
 - More robust CD8 T-cell responses, which are notoriously difficult to induce with E7
 - Increased functionality of the induced CD8 T-cells
- Highly sought-after features especially for therapeutic vaccination



fima VACC

PROGRESS OF THE **fima***VACC* PROGRAMME

- Growing robust evidence, with Phase I study published
 - The full study results were published early January 2021 in Frontiers in Immunology^{*}, a high impact immunology journal
 - Patent portfolio covering several use areas latest US patent granted in June covering the use with immune checkpoint inhibitors
 - Recently strengthened the organisation with highly skilled resources in clinical science and business development
 - Next step: moving to Phase II with a partner or by ourselves (proof-of-concept in a disease setting)





Patented disposable "band-aid-like" device for user-friendly illumination of the vaccination site



fima*NAc* – efficient and targeted intracellular delivery of nucleic acid therapeutics



Compelling preclinical results

 Strong data for a range of nucleic acid therapeutics and works in synergy with several vehicles

Addressing a major hurdle for this class of drugs

 Intracellular delivery of sufficiently high payloads remain a major obstacle for many applications

Collaborations with several players in the field

 Strategy to build a range of partnerships for different applications with a clear technology fit



fima*NAC*

INTRATUMOURAL DELIVERY WITH **fimaNAC** IS CONVINCINGLY SUPERIOR TO LNPS

Substantially higher and more targeted mRNA delivery to tumours compared to LNPs

LNPs vs fimaNAc/naked mRNA. 3 µg LNPs and fimaNAc/naked mRNA in mRNA. Mean +/- SD. same animal. 12 µg mRNA 60 0 00 1000 000 protein) (RLU/mg protein) 50 0 00 100 000 ВШ 40 0 00 fimaNAc (RLU/ 30 0 00 10 0 00 LNP 20 0 00 Biolumir 1 000 Ę 10000 Bio 100 LNPs mRNA PCI 0.003/6 1 2 min Animal no.

Consistently improves delivery compared to LNPs

- 35x higher activity with fimaNAc compared to LNPs (3μg mRNA)
- > 200x in intra-animal (2 tumours) comparison (12µg mRNA)

Luciferase expression in MC38 tumours and liver after intratumoural delivery of luciferase mRNA by LNPs or PCI. Median values.

fimaNAc -mediated delivery confined to tumour

PCI, 3 µg

mRNA

PCI, 12 μg

mRNA

PCI, 25 μg

mRNA

LNP, 25 μg

mRNA

0.0001

PBS

LNP, 3 μg

mRNA

LNP, 12 μg

mRNA


LNPs seem to leak out and leading to unwanted expression in the liver



Preventing undesirable off-target delivery

NAKED MRNA DELIVERY WITH **fimaNAc** – DIFFERENT APPLICATIONS

Substantially enhanced delivery to tumour, muscle and skin



Local delivery technology

- Delivery demonstrated to tumour, muscle, and skin
- Convincing superiority to LNPs demonstrated in tumour
- Administered as one injection without side effects
- Injection and illumination as one procedure
- mRNA expression spatially restricted to illuminated area
- Clinically proven platform technology
 - fimaVACC and fimaCHEM using the same platform technology
 - Ample safety data in humans systemic and local administration
- ► Applications where a local effect may be desired
 - Skin, muscles, tumours, eye, joints, lymph nodes



RESEARCH COLLABORATIONS

- Collaborations within fimaNAc and fimaVAcc
- Currently five collaborations, spanning across different classes of drugs and therapeutic applications
- Providing valuable scientific knowhow, encouraging results and intellectual property
- The most recently established collaboration is with OliX Pharmaceuticals, a South Korean biotech company with a novel RNAi technology
- ► PCI Biotech continues to pursue new and value-adding collaborative opportunities









GOOD PROGRESS AND EXCITING OUTLOOKS





Q&A


INVESTMENT HIGHLIGHTS

Broad platform technology	PCI is a platform technology with three programmes targeting an attractive and growing oncology market, with a clear path to a high unmet need orphan oncology market for the lead candidate
Advanced lead product candidate	fima <i>CHEM</i> – Amphinex [®] is an orphan designated (EU, US, South Korea) first-in-class product candidate in pivotal development for treatment of bile duct cancer – a disease without approved drugs
Encouraging clinical results	Positive early signs of tumour response in a first-in-man study published in Lancet Oncology, and in a Phase I study specifically targeting bile duct cancer – encouraging survival data
Defined development strategy	Development strategy for lead candidate established based on thorough regulatory discussions with FDA and EMA – a single randomised pivotal study with accelerated/conditional approval potential
Pipeline opportunities	fime VACC – a clinical stage vaccination technology with encouraging cellular immune responses fime NAC – a preclinical gene therapy delivery solution with established key player collaborations
Experienced leadership	Management team, Board of Directors and advisors with extensive pharmaceutical industry experience across a range of medical development and commercial areas



18

PCI Biotech



For enquiries:

Per Walday, CEO Mobile phone: +47 917 93 429 E-mail: <u>pw@pcibiotech.com</u> Ronny Skuggedal, CFO Mobile phone: +47 940 05 757 E-mail: <u>rs@pcibiotech.com</u>

www.pcibiotech.com

